Head-to-head evidence
CPT31 vs LP-98
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV gp41 · full HIV pipeline
CPT31
Developed by Navigen
NCT04672083 · Phase 1 · completed
The study randomly assigned healthy volunteers to CPT31 or matching placebo and blinded participants, care providers, investigators, and outcome assessors, which are the hallmarks of a well-controlled study. It reported that no participant in any group, active or placebo, had a serious adverse event, but the study measured only safety and drug levels in healthy volunteers rather than any HIV outcome.
LP-98
Developed by Shanxi Kangbao Biological Product
NCT06560489 · Phase 1/2 · completed
The study randomly assigned 40 participants to four blinded LP-98 dose groups, but it did not include a placebo or active-control arm. Its primary outcomes were laboratory, vital-sign, and electrocardiographic measures rather than hard clinical outcomes, and the primary results are not yet available.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CPT31's landscape · LP-98's landscape